Just wondering what is the consensus view from other A2M shareholders about the fact that on 1 January 2018 other IF companies (example BUB /WHA & BAL?) will no longer be able to sell their formula directly into China as the products themselves do not have the appropriate Chinese certifications in place?
I can only see this will significantly increase sales and SP after this date passes as it will allow A2M to grab more market share in the lucrative Chinese IF market since they have got CFDA approval in place .
CFDA China Deadline 2018
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.77 |
Change
0.130(1.96%) |
Mkt cap ! $4.894B | |||
| Open | High | Low | Value | Volume |
| $6.63 | $6.77 | $6.63 | $10.00M | 1.485M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2420 | $6.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.77 | 37726 | 4 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| A2M (ASX) Chart |